Outcomes of Interest
The primary outcome of this study is to determine the aetiology of non-traumatic coma in African children. The secondary outcome is to determine the overall morbidity (particularly neurological and cognitive-behavioural sequelae) and mortality of disease-specific states with non-traumatic coma in African children. These outcomes will provide critical data needed to inform future directions for research.
Protocol Development and Registration
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses Protocols (PRISMA-P) was used to develop this protocol (14) (Table 1), and we will use elements of the Cochrane Handbook of Systematic Reviews to guide the systematic review (15). The Population, Intervention, Comparator, Outcome and Study Designs (PICOS) framework was used to develop the inclusion and exclusion criteria (13). This review is registered in PROSPERO International Prospective Register of Systematic Reviews (CRD42020141937).
Eligibility Criteria
Studies of all design methods, including cohort studies and randomised-controlled trials, that are either prospective or retrospective will be included. Studies from any country in Africa will be considered, including those from multi-centre trials with data for children from African countries which can be uniquely identified. Publication dates and language will not be restricted. However, case reports, case series, commentaries and editorials will be excluded from the review. We will exclude all publications which do not contain primary data.
Studies with a primary focus of acute non-traumatic coma in children (1 month-16 years old), particularly those diagnosed with febrile encephalopathy or suspected central nervous system infection (as defined by BCS≤2, or equivalent as per a coma assessment tool) will be included. Disease-specific studies will also be included providing coma is associated and reported.
Electronic Search Strategy
We will search the following databases: (1) MEDLINE, (2) Embase, and (3) Scopus from inception. The complete search strategy for MEDLINE is included in Table 2. We will search conference proceedings and databases of ongoing studies to identify studies not found in the databases listed above. Reference lists of eligible studies and relevant systematic reviews will be searched to identify additional studies to be considered for inclusion. All records identified from the search will be imported to EndNote X9.3.1 (Clarivate Analytics, Philadelphia, PA), a citation management programme, following which duplicates will be removed.
Screening and Selection Criteria
Two authors (SR and CF) will independently screen the title and abstract of each publication. Those articles obviously irrelevant to the review, or which do not clearly meet the inclusion criteria will be excluded. The number of records screened and excluded will be recorded. The full text of the identified studies will then be individually assessed for eligibility against the pre-determined criteria, by three reviewers (CF, SR, and AB). Discrepancies will be resolved by internal discussion and consultation with an additional author (MG) if required. The reasons for exclusion of full-text articles will be documented.
Data Extraction
We will use the Cochrane Effective Practice and Organisation of Care (EPOC) standard data collection form and adapt it for study characteristics and outcome data (17). Two review authors will pilot the form on a randomly selected subset of 10% of included studies.
The following information will be extracted from each included trial:
- Author and Publication Details: Name of first author, corresponding author, publication year and journal, PubMed and registration ID, and funding source.
- Study Characteristics: Study design, duration, location(s), setting, timing of data collection (prospective or retrospective), methods of recruitment, duration of follow-up and statistical methods, completeness of outcome data, and Cochrane variables of bias (16).
- Participants: Number, age range, mean age, gender, definition of coma, inclusion and exclusion criteria, withdrawals and exclusions, method of diagnosis (microbiological methods used, including culture and polymerase chain reaction (PCR) methods), co-morbidities, and other relevant characteristics, such as human immunodeficiency virus (HIV) and nutritional status.
- Outcome: Clinical diagnosis, microbiological diagnosis, clinical outcome, such as fatality or neurological and/or neurocognitive sequelae for each clinical syndrome, and microbiological diagnosis. Neurological sequelae stratified into subtypes including motor, vision, hearing, epilepsy, and cognitive-behavioural.
Attempts to contact authors will be made for missing outcome data or of key study characteristics.
Assessment of Risk of Bias
Three reviewers (CF, SR, and AB) will independently conduct a bias risk assessment at the study level in order to assess the quality of the included studies. The validated Cochrane Collaboration Risk of Bias tool (16) will be used as a framework upon which to guide quality assessments for randomised controlled trials. The Newcastle-Ottawa Scale (NOS) will be used for case-control and cohort studies. Critical Appraisal Skills Programme (CASP) checklists will be used for other study types (18,19).
Risk of bias for each domain will be recorded as high, low, or unclear. Any disagreements will be discussed with a third reviewer (MG).
Data Synthesis
Because of concerns about meta-analysis of proportions on very heterogeneous populations, we plan a meta-analysis of outcome stratified by inclusion criteria where possible. A narrative synthesis of the data will also be provided including summary and explanation of characteristics and findings of included studies per outcome. Mortality will be presented as a simple proportion with exact binomial confidence intervals, and pooled mortality estimates will be calculated using generalised linear mixed models (a normal-binomial model). For interventional studies, the outcomes in the usual care arm of the study only will be included in these estimates. Heterogeneity will be quantified with τ2, I2, and Cochran’s Q test. Exploratory meta-regression will be undertaken to explore heterogeneity by including covariates as fixed effects (e.g. year of recruitment, proportion of patients infected with HIV, median age) and testing for improved model fit by likelihood ratio testing of nested models. A p value of < 0.05 will be considered a statistically significantly improved fit. Summary estimates of one month mortality, where available, will be considered together and presented in the same way. Pooled prevalence estimates of malaria, acute bacterial or viral meningitis, encephalitis and bloodstream infection, will be calculated using random effects meta-analysis as above. For these aetiology analyses, we will include all studies, regardless of coma definition, and will include both usual care and intervention arms of RCTs. A sensitivity analysis will also be performed at the outcome level using the high-quality studies only (15). A table of study characteristics will be provided and the risk of bias for included studies will be described throughout the synthesis.